The trademark application ARTEMIS was filed by Eureka Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on June 20, 2022, and it was registered by office on September 27, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on August 28, 2024.
Goods And Services
The mark was filed in class 1 with following description of goods:
Cells and molecules for scientific and research use
Cells and molecules for the experimental production of pharmaceutical and biotechnological preparations
Active chemical ingredients for use in the manufacture of anti-cancer drugs
Antibodies, T cells, modified T cells and T-Cell Receptors (TCRs) for scientific and research purposes
Nucleic acids and genetic molecules encoding T-Cell Receptors (TCRs) for scientific and research purposes.